Soren Dahl is the visionary CEO and Founder of Gambit Bio LLC, a pioneering biotechnology firm dedicated to developing innovative gene-editing solutions for rare genetic disorders. With over 15 years of experience in the biotech industry, Soren has successfully led Gambit Bio from a startup to a leader in the field, securing over $150 million in funding and establishing strategic partnerships with major pharmaceutical companies. His commitment to advancing healthcare through cutting-edge technology has earned him recognition as one of Forbes' Top 50 Healthcare Innovators. Soren holds a Ph.D. in Molecular Biology from Stanford University and is passionate about fostering a culture of innovation and collaboration within his team.More...